Why the study?
Traditional CKD management strategies proved only partially effective at preventing the progressive decline in renal function and associated cardiovascular risk.
Do SGLT2 inhibitors and incretins slow down the decline in renal function and improve cardiovascular prognosis in patients with chronic kidney disease?
Population
Patients with chronic kidney disease (CKD), with or without type 2 diabetes
Comparison
SGLT2 inhibitors (glyphozines) and incretins vs Standard therapy including strict control of…
Design
Review
Authors
Loading...
CKD-CV risk link warrants clinical vigilance; leaves open optimal syndrome definition for validation.
Do SGLT2 inhibitors and incretins slow down the decline in renal function and improve cardiovascular prognosis in patients with chronic kidney disease?
SGLT2 inhibitors and incretins represent a paradigm shift as cardio-nephro-metabolic therapies that effectively slow CKD progression and improve cardiovascular outcomes.
Cice et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: